1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Genomics In Cancer Care Market Size Growth Rate by Type: 2018 VS 2022 VS 2030
1.2.2 Instruments
1.2.3 Consumables
1.2.4 Services
1.3 Market by Application
1.3.1 Global Genomics In Cancer Care Market Share by Application: 2018 VS 2022 VS 2030
1.3.2 Diagnostics
1.3.3 Personalized Medicine
1.3.4 Drug Discovery
1.3.5 Development
1.3.6 Research
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Genomics In Cancer Care Market Perspective (2018-2030)
2.2 Genomics In Cancer Care Growth Trends by Region
2.2.1 Genomics In Cancer Care Market Size by Region: 2018 VS 2022 VS 2030
2.2.2 Genomics In Cancer Care Historic Market Size by Region (2018-2023)
2.2.3 Genomics In Cancer Care Forecasted Market Size by Region (2023-2030)
2.3 Genomics In Cancer Care Market Dynamics
2.3.1 Genomics In Cancer Care Industry Trends
2.3.2 Genomics In Cancer Care Market Drivers
2.3.3 Genomics In Cancer Care Market Challenges
2.3.4 Genomics In Cancer Care Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Genomics In Cancer Care Players by Revenue
3.1.1 Global Top Genomics In Cancer Care Players by Revenue (2018-2023)
3.1.2 Global Genomics In Cancer Care Revenue Market Share by Players (2018-2023)
3.2 Global Genomics In Cancer Care Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Genomics In Cancer Care Revenue
3.4 Global Genomics In Cancer Care Market Concentration Ratio
3.4.1 Global Genomics In Cancer Care Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Genomics In Cancer Care Revenue in 2022
3.5 Genomics In Cancer Care Key Players Head office and Area Served
3.6 Key Players Genomics In Cancer Care Product Solution and Service
3.7 Date of Enter into Genomics In Cancer Care Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Genomics In Cancer Care Breakdown Data by Type
4.1 Global Genomics In Cancer Care Historic Market Size by Type (2018-2023)
4.2 Global Genomics In Cancer Care Forecasted Market Size by Type (2023-2030)
5 Genomics In Cancer Care Breakdown Data by Application
5.1 Global Genomics In Cancer Care Historic Market Size by Application (2018-2023)
5.2 Global Genomics In Cancer Care Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Genomics In Cancer Care Market Size (2018-2030)
6.2 North America Genomics In Cancer Care Market Size by Country (2018-2023)
6.3 North America Genomics In Cancer Care Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Genomics In Cancer Care Market Size (2018-2030)
7.2 Europe Genomics In Cancer Care Market Size by Country (2018-2023)
7.3 Europe Genomics In Cancer Care Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Genomics In Cancer Care Market Size (2018-2030)
8.2 Asia-Pacific Genomics In Cancer Care Market Size by Country (2018-2023)
8.3 Asia-Pacific Genomics In Cancer Care Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Genomics In Cancer Care Market Size (2018-2030)
9.2 Latin America Genomics In Cancer Care Market Size by Country (2018-2023)
9.3 Latin America Genomics In Cancer Care Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Genomics In Cancer Care Market Size (2018-2030)
10.2 Middle East & Africa Genomics In Cancer Care Market Size by Country (2018-2023)
10.3 Middle East & Africa Genomics In Cancer Care Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Detail
11.1.2 Illumina Business Overview
11.1.3 Illumina Genomics In Cancer Care Introduction
11.1.4 Illumina Revenue in Genomics In Cancer Care Business (2018-2023)
11.1.5 Illumina Recent Development
11.2 Thermo Fisher scientific
11.2.1 Thermo Fisher scientific Company Detail
11.2.2 Thermo Fisher scientific Business Overview
11.2.3 Thermo Fisher scientific Genomics In Cancer Care Introduction
11.2.4 Thermo Fisher scientific Revenue in Genomics In Cancer Care Business (2018-2023)
11.2.5 Thermo Fisher scientific Recent Development
11.3 Agilent
11.3.1 Agilent Company Detail
11.3.2 Agilent Business Overview
11.3.3 Agilent Genomics In Cancer Care Introduction
11.3.4 Agilent Revenue in Genomics In Cancer Care Business (2018-2023)
11.3.5 Agilent Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Genomics In Cancer Care Introduction
11.4.4 Roche Revenue in Genomics In Cancer Care Business (2018-2023)
11.4.5 Roche Recent Development
11.5 Cancer Genetics
11.5.1 Cancer Genetics Company Detail
11.5.2 Cancer Genetics Business Overview
11.5.3 Cancer Genetics Genomics In Cancer Care Introduction
11.5.4 Cancer Genetics Revenue in Genomics In Cancer Care Business (2018-2023)
11.5.5 Cancer Genetics Recent Development
11.6 Beckman Coulter
11.6.1 Beckman Coulter Company Detail
11.6.2 Beckman Coulter Business Overview
11.6.3 Beckman Coulter Genomics In Cancer Care Introduction
11.6.4 Beckman Coulter Revenue in Genomics In Cancer Care Business (2018-2023)
11.6.5 Beckman Coulter Recent Development
11.7 Bio-Rad
11.7.1 Bio-Rad Company Detail
11.7.2 Bio-Rad Business Overview
11.7.3 Bio-Rad Genomics In Cancer Care Introduction
11.7.4 Bio-Rad Revenue in Genomics In Cancer Care Business (2018-2023)
11.7.5 Bio-Rad Recent Development
11.8 Danaher
11.8.1 Danaher Company Detail
11.8.2 Danaher Business Overview
11.8.3 Danaher Genomics In Cancer Care Introduction
11.8.4 Danaher Revenue in Genomics In Cancer Care Business (2018-2023)
11.8.5 Danaher Recent Development
11.9 Sigma Aldrich
11.9.1 Sigma Aldrich Company Detail
11.9.2 Sigma Aldrich Business Overview
11.9.3 Sigma Aldrich Genomics In Cancer Care Introduction
11.9.4 Sigma Aldrich Revenue in Genomics In Cancer Care Business (2018-2023)
11.9.5 Sigma Aldrich Recent Development
11.10 Pacific Biosciences
11.10.1 Pacific Biosciences Company Detail
11.10.2 Pacific Biosciences Business Overview
11.10.3 Pacific Biosciences Genomics In Cancer Care Introduction
11.10.4 Pacific Biosciences Revenue in Genomics In Cancer Care Business (2018-2023)
11.10.5 Pacific Biosciences Recent Development
11.11 Quest Diagnostics
11.11.1 Quest Diagnostics Company Detail
11.11.2 Quest Diagnostics Business Overview
11.11.3 Quest Diagnostics Genomics In Cancer Care Introduction
11.11.4 Quest Diagnostics Revenue in Genomics In Cancer Care Business (2018-2023)
11.11.5 Quest Diagnostics Recent Development
11.12 Luminex
11.12.1 Luminex Company Detail
11.12.2 Luminex Business Overview
11.12.3 Luminex Genomics In Cancer Care Introduction
11.12.4 Luminex Revenue in Genomics In Cancer Care Business (2018-2023)
11.12.5 Luminex Recent Development
11.13 Oxford Gene Technology
11.13.1 Oxford Gene Technology Company Detail
11.13.2 Oxford Gene Technology Business Overview
11.13.3 Oxford Gene Technology Genomics In Cancer Care Introduction
11.13.4 Oxford Gene Technology Revenue in Genomics In Cancer Care Business (2018-2023)
11.13.5 Oxford Gene Technology Recent Development
11.14 PerkinElmer
11.14.1 PerkinElmer Company Detail
11.14.2 PerkinElmer Business Overview
11.14.3 PerkinElmer Genomics In Cancer Care Introduction
11.14.4 PerkinElmer Revenue in Genomics In Cancer Care Business (2018-2023)
11.14.5 PerkinElmer Recent Development
11.15 Qiagen
11.15.1 Qiagen Company Detail
11.15.2 Qiagen Business Overview
11.15.3 Qiagen Genomics In Cancer Care Introduction
11.15.4 Qiagen Revenue in Genomics In Cancer Care Business (2018-2023)
11.15.5 Qiagen Recent Development
11.16 GE Healthcare
11.16.1 GE Healthcare Company Detail
11.16.2 GE Healthcare Business Overview
11.16.3 GE Healthcare Genomics In Cancer Care Introduction
11.16.4 GE Healthcare Revenue in Genomics In Cancer Care Business (2018-2023)
11.16.5 GE Healthcare Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
